Clinical Trial Update: SSAT063- Pharmacokinetics of Efavirenz 400 mg Once Daily During Pregnancy in HIV-1 Infected Women [Phase 1]

View source ↗

Summary

Phase 1 pharmacokinetic study evaluating efavirenz 400 mg once daily in HIV-1 infected pregnant women. The trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection

Drugs mentioned

• efavirenz (Sustiva) (efavirenz)

Snippet

Sponsor: St Stephens Aids Trust | Conditions: HIV | Phase 1 | Status: COMPLETED